Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

Open access


Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model.

Methods. Thirty Sprague-Dawley male rats were divided into 3 main groups: control, rats with type 2 diabetes mellitus (T2DM), and T2DM rats treated with darapladib (T2DM-DP). Each group was divided into 2 subgroups according the time of treatment: 8-week and 16-week treatment group. Fasting blood glucose, insulin resistance, and lipid profile were measured and analyzed to ensure T2DM model. The foam cells number were detected using hematoxylin-eosin (HE) staining and the expression of iNOS and ICAM-1 was analyzed using double immunofluorescence staining.

Results. Induction of T2DM in male Sprague-Dawley rats after high fat diet and streptozotocin injection was confirmed by elevated levels of total cholesterol and LDL and increased fasting glucose and insulin levels compared to controls after both times of treatment. Moreover, T2DM in rats induced a significant increase (p<0.05) in the foam cells number and iNOS and ICAM-1 expression in aorta compared to controls after both treatment times. Darapladib treatment significantly reduced (p<0.05) foam cells number as well as iNOS expression in aorta in rats with T2DM after both treatment times. A significant decrease (p<0.05) in ICAM-1 expression in aorta was observed after darapladib treatment in rats with T2DM only after 8 weeks of treatment.

Conclusion. Our data indicate that darapladib can decrease the foam cells number, iNOS, and ICAM-1 expression in aorta at the early stages of atherosclerosis in T2DM rat model.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 34 Suppl 1 S62–S69 2011.

  • Aronson D Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 1 1–10 2002.

  • Avogaro A Albiero M Menegazzo L de Kreutzenberg S Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34 S285–290 2011.

  • Burns TA Geor RJ Mudge MC McCutcheon LJ Hinchcliffe KW Belknap JK. Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin-resistant and insulin-sensitive light breed horses. J Vet Intern Med 24 932–939 2010.

  • Cacho J Sevillano J de Castro J Herrera E Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague Dawley rats. Am J Physiol Endocrinol Metab 295 E1269–E1276 2008.

  • Carlquist JF Muhlestein JB Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Mol Diagn 7 511–517 2007.

  • Chait A Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 50 S335–S339 2009.

  • Fukuchi M Giaid A. Endothelial expression of endothelial nitric oxide synthase and endothelin-1 in human coronary artery disease: specific reference to underlying lesion. Journal of Technical Methods and Pathology 79 659–670 1999.

  • Galkina E Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27 2292–2301 2007.

  • Heriansyah T Wihastuti TA Anita KW Iskandar A Suhendra RB Setiabudi PA Sishartami LW. Atherogenesis inhibition by darapladib administration in dyslipidemia model sprague-dawley rats. National Journal of Physiology Pharmacy and Pharmacology 6 52–58 2015.

  • Heriansyah T Adam AA Wihastuti TA Rohman MS. Elaborate evaluation of serum and tissue oxidized LDL level with darapladib therapy: a feasible diagnostic marker for early atherogenesis. Asian Pacific Journal of Tropical Biomedicine 7 134–138 2016.

  • Hu MM Zhang J Wang WY Wu WY Ma YL Chen WH Wang YP. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin 32 1253–1258 2011.

  • International Diabetes Federation: IDF Diabetes Atlas (6nd ed.) 2013.

  • Navale AM Paranjape AN. Role of inflammation in development of diabetic complications and commonly used inflammatory markers with respect to diabetic complications. Int J Pharm Pharm Sci 5 1–5 2013.

  • Samuel VT Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 148 852–871 2012.

  • Silva IT Mello APQ Damasceno NRT. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids in Health and Disease 10 170 2010.

  • Silvana GT Rifa’i M. Activity test of Vip Albumin against blood glucose levels and lymphocytes profiles in Balb/c mice as type 2 diabetes mellitus model. Jurnal Biotropika 3 17–20 2015.

  • Sumagin R Lomakina E Sarelius IH. Leukocyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol 295 H969–H977 2008.

  • Thompson PL Nidorf SM Eikelboom J. Targeting the unstable plaque in acute coronary syndromes. Clin Ther 35 1099–1107 2013.

  • Turan B Dhalla NS. Diabetic cardiomyopathy: biochemical and molecular mechanism. Springer New York 2014.

  • Van Dijk JW Venema M van Mechelen W Stehouwer CD Hartgens F van Loon LJ. Effect of moderate-intensity exercise versus activities of daily living on 24-hour blood glucose homeostasis in male patients with type 2 diabetes. Diabetes Care 36 3448–3453 2013.

  • Wang W-y Zhang J Wu W-y Li J Ma Y-l Chen W-h Yan H Wang K Xu WW Shen JH Wang YP. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS ONE 6 e23425 2011.

  • Wihastuti TA Sargowo D Tjokroprawiro A Permatasari N Widodo MA Soeharto S. Vasa vasorum anti-angiogenesis through H2O2 HIF-1α NF-κB and iNOS inhibition by mangosteen pericarp ethanolic extract (garcinia mangostana linn) in hypercholesterol-diet-given rattus norvegicus wistar strain. Vasc Health Risk Manag 10 523–531 2014.

  • Wihastuti TA Heriansyah H Soraya M Wijayanti M Firani NK Iskandar A Anita KW Agustin D Pujiana L Sandika N Ardyanto E Puji A Wiji Y Febriato A Nuraminudin A Quirino F Rachmawati S Candra Y. Inhibition of oxidative stress in hypercholesterolemic rats by soy milk. Journal of Cardiovascular Disease Research 7 74–82 2016.

  • Wilensky RL Shi Y Mohler ER 3rd Hamamdzic D Burgert ME Li J Postle A Fenning RS Bollinger JG Pelchovitz DJ Yang J Mirabile RC Webb CL Zhang L Zhang P Gelb MH Walker MC Zalewski A Macphee CH. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14 1059–66 2008.

Journal information
Impact Factor

CiteScore 2018: 1.27

SCImago Journal Rank (SJR) 2018: 0.411
Source Normalized Impact per Paper (SNIP) 2018: 0.441

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 806 411 35
PDF Downloads 493 286 35